The cytidine analogue, 5-azacytidine (AZA; 5-AZA-cR), is the primary treatment for myelodysplastic syndrome and chronic myelomonocytic leukaemia. However, only ~50% of treated patients will ...

Response to AZA therapy was defined as stable disease (temporary disease control defined by no increasing blastosis and stable chimerism), PR or CR (BM involvement with <5% blasts or normalization ...